Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 15/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271780 | 0.93 | HPGDS (0.43) | HPGDSPAK1GRIN2BKCNH2CYP2D6 | |
| SCHEMBL14349399 | 0.91 | PAK1 (0.45) | HPGDSPAK1GRIN2BKCNH2CYP2D6 | |
| SCHEMBL5658584 | 0.91 | PAK1 (0.46) | HPGDSPAK1GRIN2BKCNH2CYP2D6 | |
| SCHEMBL14349445 | 0.91 | PAK1 (0.45) | HPGDSPAK1GRIN2BKCNH2CYP2D6 | |
| SCHEMBL8271772 | 0.91 | HPGDS (0.43) | HPGDSPAK1GRIN2BKCNH2CYP2D6 | |
| SCHEMBL5660340 | 0.91 | LMNA (0.45) | HPGDSPAK1GRIN2BKCNH2CYP2D6 | |
| SCHEMBL8271777 | 0.89 | PAK1 (0.48) | HPGDSPAK1GRIN2BKCNH2CYP2D6 | |
| SCHEMBL14349479 | 0.89 | GRIN2B (0.51) | HPGDSPAK1GRIN2BKCNH2CYP2D6 | |
| SCHEMBL8271774 | 0.89 | HPGDS (0.41) | HPGDSPAK1GRIN2BKCNH2CYP2D6 | |
| SCHEMBL8271775 | 0.87 | PAK1 (0.44) | HPGDSPAK1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367560-A1 | Methods for Treating Parkinson's Disease | UCB PHARMA, S.A. (BE) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367560-A1 | Methods for Treating Parkinson's Disease | ADORA2A, GRIN2A, GRIN3A | HPGDS 2591/4885PAK1 1830/4885GRIN2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.